ClinicalTrials.gg
CompletedNCT01941940Updated Jul 11, 2017Results posted

A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants

A Phase 3 interventional study of Tocilizumab and DMARDs in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 49 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-11.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
227
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
28th of 110
227 · median 97
Started
2013
with 8 others
Phase 3
65 of 110
none open now
Registered
75th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 28th largest by enrollment, is one of 9 that started in 2013, is one of 65 in phase 3, and was the 75th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This open-label, single arm, Phase 3b study will evaluate the efficacy of tocilizumab (RoActemra), administered as monotherapy or in combination with methotrexate and/or other DMARDs, in participants with moderate to severe active RA.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of active RA according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria
  • Moderate to severe RA (CDAI at least [>/=] 10 and DAS28 >/=3.2) at screening
  • Tumor necrosis factor inhibitors-inadequate responder (TNF-IR), methotrexate-inadequate responder (MTX-IR), and/or DMARDs-inadequate responder (DMARDs-IR)
  • Oral (less than or equal to [\</=] 10 mg per day prednisone or equivalent) and non-steroidal anti-inflammatory drugs (NSAIDs; up to the maximum recommended dose) are permitted if on a stable dose regimen for >/=4 weeks prior to baseline
  • Permitted non-biologic DMARDs are allowed if at a stable dose for >/=4 weeks prior to baseline
  • Receiving treatment on an outpatient basis, not including tocilizumab
  • Females of and males with female partners of childbearing potential must agree to use a reliable means of for at least 3 months following the last dose of tocilizumab

Exclusion criteria

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 12 months following baseline
  • Rheumatic disease other than RA; secondary Sjögren's syndrome with RA is permitted
  • Functional Class IV as defined by the ACR Classification of Functional Status in RA
  • Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16
  • Prior history of or current inflammatory joint disease other than RA
  • Exposure to tocilizumab (either intravenous [IV] or SC) at any time prior to baseline
  • Treatment with any agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening
  • Previous treatment with any cell-depleting therapies
  • Intra-articular or parenteral within 4 weeks prior to baseline
  • History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
  • Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine (including uncontrolled diabetes mellitus), or gastrointestinal disease
  • Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections
  • Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening
  • Active tuberculosis (TB) requiring treatment within the previous 3 years
  • Positive for surface antigen or antibody
  • Primary or secondary immunodeficiency (history of or currently active)
  • Evidence of active malignant disease, diagnosed within the previous 10 years (except for basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured), or breast cancer diagnosed within the previous 20 years
  • Pregnant or breast feeding women
  • Neuropathies or other conditions that might interfere with pain evaluation
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
227 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Tocilizumab at a fixed dose of 162 milligrams (mg) will be administered as subcutaneous (SC) injection alone or along with methotrexate and/or other non-biological DMARDs irrespective of body weight, once every week for a total of 52 weeks. After 52-weeks of treatment, at the discretion of the treating physician, participants can continue the study treatment with SC tocilizumab until it becomes commercially available in Italy.

    Drug: Tocilizumab · Drug: DMARDs

Interventions

  • Tocilizumab at a fixed dose of 162 mg as SC injection will be administered once every week.

    Also known as: RoActemra

  • DrugDMARDs

    Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

    The CDAI is a numerical sum of 4 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) based on a 28-joint assessment, patient's global assessment of disease activity (PtGDA) and physician global assessment of disease activity (PGDA) assessed on 0-10 centimeters (cm) visual analogue scale (VAS). Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score less than or equal to (\</=) 2.8 indicates disease remission, greater than (\>) 2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

    Time frame: Baseline, Week 24

  2. Change From Baseline in CDAI at Week 20

    The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

    Time frame: Baseline, Week 20

  3. Change From Baseline in CDAI at Week 16

    The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

    Time frame: Baseline, Week 16

  4. Change From Baseline in CDAI at Week 12

    The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

    Time frame: Baseline, Week 12

  5. Change From Baseline in CDAI at Week 8

    The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

    Time frame: Baseline, Week 8

  6. Change From Baseline in CDAI at Week 4

    The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

    Time frame: Baseline, Week 4

  7. Change From Baseline in CDAI at Week 2

    The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

    Time frame: Baseline, Week 2

Secondary outcomes

  1. Number of Participants Achieving Clinical Remission According to CDAI up to Week 52

    The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 during any two consecutive visits, not including the baseline visit indicates disease remission.

    Time frame: Baseline up to Week 52 (Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 38, and 52)

  2. Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (DAS28-ESR) at Weeks 2, 24, and 52

    DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hour) and PtGDA assessed on 0-10 cm VAS. Higher scores indicate greater affectation due to disease activity. DAS28-ESR total score= 0-9.4. DAS28-ESR \</=3.2 indicates low disease activity, DAS28-ESR \>3.2 to 5.1 indicates moderate to high disease activity, and DAS28-ESR \</=3.2 indicates remission.

    Time frame: Baseline, Weeks 2, 24, and 52

  3. Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 24, and 52

    SDAI is a numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and C-reactive protein (CRP) in milligrams per deciliter (mg/dL). Higher scores indicate greater affectation due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity, \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity.

    Time frame: Baseline, Weeks 2, 24, and 52

  4. Percentage of Participants With an American College of Rheumatology 20% (ACR20), 50% (ACR50), and 70% (ACR70) Response

    The ACR 20, 50, and 70 responses: greater than or equal to (\>/=) 20 percent (%), 50%, and 70% improvement in TJC and SJC (28 assessed joints), and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP or ESR at each visit.

    Time frame: Weeks 2, 24, and 52

  5. Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28

    The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 \</=3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1; non-responders: change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1.

    Time frame: Baseline, Weeks 2, 24, and 52

  6. Change From Baseline in Total TJC at Weeks 2, 24, and 52

    TJC was defined as the total number of painful joints based on 68-joint assessment (TJC-68) and 28-joint assessment (TJC-28).

    Time frame: Baseline, Weeks 2, 24, and 52

  7. Change From Baseline in Total SJC at Weeks 2, 24, and 52

    SJC was defined as the total number of swollen joints based on 66-joint assessment (SJC-66) and 28-joint assessment (SJC-28).

    Time frame: Baseline, Weeks 2, 24, and 52

  8. Association Between Disease Activity Parameters: DAS28-ESR and CDAI, Assessed Using Correlation Coefficient

    DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. Higher scores indicate greater affectation due to disease activity. The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. Higher scores represent greater affectation due to disease activity. Correlation coefficient for relationship between DAS28-ESR and CDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship.

    Time frame: Weeks 2, 24, 52

  9. Association Between Disease Activity Parameters: DAS28-ESR and SDAI, Assessed Using Correlation Coefficient

    DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. Higher scores indicate greater affectation due to disease activity. SDAI is a numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. Higher scores indicate greater affectation due to disease activity. Correlation coefficient for relationship between DAS28-ESR and SDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship.

    Time frame: Weeks 2, 24, 52

  10. Association Between Disease Activity Parameters: CDAI and SDAI, Assessed Using Correlation Coefficient

    The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. Higher scores represent greater affectation due to disease activity. SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. Higher scores indicate greater affectation due to disease activity. Correlation coefficient for relationship between CDAI and SDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship.

    Time frame: Weeks 2, 24, 52

  11. Association Between Disease Activity Parameter (DAS28-ESR) and Treatment Response Parameters (ACR20, ACR50, and ACR70), Assessed Using Regression Coefficient

    DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. The ACR 20, 50, and 70 responses: \>/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between DAS28-ESR and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.

    Time frame: Weeks 2, 24, 52

  12. Association Between Disease Activity Parameter (DAS28-ESR) and Treatment Response Parameter (EULAR), Assessed Using Regression Coefficient

    DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. EULAR response criteria (based on DAS28 score): Good responders (change from baseline \>1.2 with DAS28 \</=3.2); Moderate responders (change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1); Non-responders (change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1). Regression coefficient for relationship between DAS28-ESR and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.

    Time frame: Weeks 2, 24, 52

  13. Association Between Disease Activity Parameter (CDAI) and Treatment Response Parameters (ACR20, ACR50, and ACR70), Assessed Using Regression Coefficient

    The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. The ACR 20, 50, and 70 responses: \>/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between CDAI and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.

    Time frame: Weeks 2, 24, 52

  14. Association Between Disease Activity Parameter (CDAI) and Treatment Response Parameter (EULAR), Assessed Using Regression Coefficient

    The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. EULAR response criteria (based on DAS28 score): Good responders (change from baseline \>1.2 with DAS28 \</=3.2); Moderate responders (change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1); Non-responders (change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1). Regression coefficient for relationship between CDAI and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.

    Time frame: Weeks 2, 24, 52

  15. Association Between Disease Activity Parameter (SDAI) and Treatment Response Parameters (ACR20, ACR50, and ACR70), Assessed Using Regression Coefficient

    SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. The ACR 20, 50, and 70 responses: \>/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between SDAI and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.

    Time frame: Weeks 2, 24, 52

  16. Association Between Disease Activity Parameter (SDAI) and Treatment Response Parameter (EULAR), Assessed Using Regression Coefficient

    The SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. EULAR response criteria (based on DAS28 score): Good responders (change from baseline \>1.2 with DAS28 \</=3.2); Moderate responders (change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1); Non-responders (change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1). Regression coefficient for relationship between SDAI and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.

    Time frame: Weeks 2, 24, 52

  17. Percentage of DMARDs Dose Reductions and/or Discontinuation Events by Reasons

    Percentage of DMARDs dose reduction and/or discontinuation (Red/Dis) events is reported by different reasons.

    Time frame: Baseline up to Week 52

  18. Percentage of Non-DMARDs Dose Reductions and/or Discontinuation Events by Reasons

    Percentage of Non-DMARDs dose reduction and/or discontinuation (Red/Dis) events is reported by different reasons.

    Time frame: Baseline up to Week 52

  19. Change From Baseline in PtGDA VAS Score at Weeks 2, 24, and 52

    Participants answered the following question: "Considering all the ways your arthritis affects you, how are you feeling today." Participants responded by using a 0 - 100 millimeter (mm) VAS, where 0 mm = very well and 100 mm = very poorly.

    Time frame: Baseline, Weeks 2, 24, and 52

  20. Change From Baseline in PGDA VAS Score at Weeks 2, 24, and 52

    The physician assessed participant's current disease activity on a 0-100 mm VAS, where 0 mm = no disease activity and 100 mm = maximum disease activity.

    Time frame: Baseline, Weeks 2, 24, and 52

  21. Participant Pain VAS Score at Weeks 2, 24, and 52

    Participants assessed their pain using a 0-100 mm VAS. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain.

    Time frame: Weeks 2, 24, and 52

  22. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Weeks 2, 24, and 52

    HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Baseline, Weeks 2, 24, and 52

  23. Missed Working Days Assessed Using Short Form-Health and Labor Questionnaire (SF-HLQ) Score at Weeks 24 and 52

    The SF-HLQ assessed productivity losses related to health problems in individuals with paid or unpaid work and consisted of three modules (absenteeism from paid work, production losses without absenteeism from paid work and hindrance in the performance of paid and unpaid work). Any missed working days or number of worked days with reduced efficiency during the last month were reported.

    Time frame: Weeks 24 and 52

  24. Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Total Score at Weeks 2, 24, and 52

    FACIT total score is sum of Functional Assessment of Cancer Therapy-General (FACT-G) score and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F; additional concerns) score. FACT-G is a core questionnaire that evaluates quality of life (QoL) in cancer population. FACT-G consists of 27 questions grouped in 4 domains of general health-related QoL: physical well-being, social/family well-being, emotional well-being, and functional well-being; each item ranges from 0 (not at all) to 4 (very much). FACT-G score ranges between 0-108. FACIT-F is a 13-item questionnaire that evaluates self-reported fatigue and its impact upon daily activities. Each item ranges from 0 (Not at all) to 4 (Very much). The sum of all responses result in the FACIT total score with a total possible range of 0 (better score) to 160 (worse score). Negative change from baseline represents a better QoL.

    Time frame: Baseline, Weeks 2, 24, and 52

  25. Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) at Weeks 24 and 52

    PSQI is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction). A participant indicates how frequently each item was experienced on a scale from 0 to 3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality. A score of \>/=5 indicates poor sleepers.

    Time frame: Baseline, Weeks 24 and 52

  26. Treatment Compliance, as Assessed Using Participant Diary Cards and Return Records

    Treatment Compliance was calculated as (total actual doses taken for the period) / (total planned or prescribed dose for the period) x 100.

    Time frame: Weeks 24 and 52

  27. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) of Special Interest

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs are AEs occurring between the first dose of study drug and up to 28 days after the last dose that were absent before treatment or that worsened relative to pre-treatment state. Following AEs were considered as AEs of special interest: anaphylactic reaction, hypersensitivity, stress cardiomyopathy, Gilbert's syndrome, gastrointestinal perforation, injection site erythema, injection site hypersensitivity, injection site irritation, injection site pruritus, arthritis bacterial, cellulitis, klebsiella infection, oral candidiasis, pneumonia, skin infection, vulvovaginal candidiasis, alanine aminotransferase increased, hepatic enzyme increased, brain neoplasm malignant, and urticaria.

    Time frame: Baseline up to 95 weeks

  28. Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to Tocilizumab

    Percentage of participants with positive results for ATA against tocilizumab at different time points is reported.

    Time frame: Baseline, Weeks 12, 24, 38, 52, at 8 weeks after last dose (up to Week 60), at early withdrawal (up to Week 52), at Follow-up Visits 1 (Week 64), 2 (Week 76), and 3 (Week 88)

  29. Mean Tocilizumab Concentration

    Time frame: Baseline, Weeks 12, 24, 38, 52, at early withdrawal (up to Week 52), at Follow-up Visit 2 (Week 76)

  30. Mean Soluble Interleukin-6 Receptor (sIL-6R) Concentration

    Time frame: Baseline, Weeks 12, 24, 38, 52, at early withdrawal (up to Week 52), at Follow-up Visit 2 (Week 76)

07

Results

Posted Dec 15, 2016

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab
Started227
Completed194
Not completed33
Withdrew: Adverse event11
Withdrew: Lost to follow-up2
Withdrew: Physician decision2
Withdrew: Withdrawal by subject15
Withdrew: Death1
Withdrew: Other1
Withdrew: Other1

Outcome measures

PrimaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

The CDAI is a numerical sum of 4 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) based on a 28-joint assessment, patient's global assessment of disease activity (PtGDA) and physician global assessment of disease activity (PGDA) assessed on 0-10 centimeters (cm) visual analogue scale (VAS). Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score less than or equal to (\</=) 2.8 indicates disease remission, greater than (\>) 2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24
units on a scaleTocilizumab
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24-21.6 ± 13.25
Statistical analysis
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
PrimaryChange From Baseline in CDAI at Week 20

The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

Time frame:
Baseline, Week 20
Reported as:
Mean · units on a scale
Change From Baseline in CDAI at Week 20
units on a scaleTocilizumab
Change From Baseline in CDAI at Week 20-21.3 ± 12.87
PrimaryChange From Baseline in CDAI at Week 16

The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

Time frame:
Baseline, Week 16
Reported as:
Mean · units on a scale
Change From Baseline in CDAI at Week 16
units on a scaleTocilizumab
Change From Baseline in CDAI at Week 16-20.2 ± 12.53
PrimaryChange From Baseline in CDAI at Week 12

The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in CDAI at Week 12
units on a scaleTocilizumab
Change From Baseline in CDAI at Week 12-19.1 ± 12.46
PrimaryChange From Baseline in CDAI at Week 8

The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

Time frame:
Baseline, Week 8
Reported as:
Mean · units on a scale
Change From Baseline in CDAI at Week 8
units on a scaleTocilizumab
Change From Baseline in CDAI at Week 8-17.7 ± 12.07
PrimaryChange From Baseline in CDAI at Week 4

The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

Time frame:
Baseline, Week 4
Reported as:
Mean · units on a scale
Change From Baseline in CDAI at Week 4
units on a scaleTocilizumab
Change From Baseline in CDAI at Week 4-14.0 ± 11.57
PrimaryChange From Baseline in CDAI at Week 2

The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

Time frame:
Baseline, Week 2
Reported as:
Mean · units on a scale
Change From Baseline in CDAI at Week 2
units on a scaleTocilizumab
Change From Baseline in CDAI at Week 2-9.1 ± 9.71
Statistical analysis
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
SecondaryNumber of Participants Achieving Clinical Remission According to CDAI up to Week 52

The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 during any two consecutive visits, not including the baseline visit indicates disease remission.

Time frame:
Baseline up to Week 52 (Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 38, and 52)
Reported as:
Number · participants
Number of Participants Achieving Clinical Remission According to CDAI up to Week 52
participantsTocilizumab
Number of Participants Achieving Clinical Remission According to CDAI up to Week 5210
SecondaryChange From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (DAS28-ESR) at Weeks 2, 24, and 52

DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hour) and PtGDA assessed on 0-10 cm VAS. Higher scores indicate greater affectation due to disease activity. DAS28-ESR total score= 0-9.4. DAS28-ESR \</=3.2 indicates low disease activity, DAS28-ESR \>3.2 to 5.1 indicates moderate to high disease activity, and DAS28-ESR \</=3.2 indicates remission.

Time frame:
Baseline, Weeks 2, 24, and 52
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (DAS28-ESR) at Weeks 2, 24, and 52
units on a scaleTocilizumab
Baseline (n=216)5.81 ± 1.080
Change at Week 2 (n=208)-1.5 ± 1.04
Change at Week 24 (n=174)-3.2 ± 1.47
Change at Week 52 (n=31)-3.6 ± 1.18
Statistical analysis
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 24, and 52

SDAI is a numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and C-reactive protein (CRP) in milligrams per deciliter (mg/dL). Higher scores indicate greater affectation due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity, \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity.

Time frame:
Baseline, Weeks 2, 24, and 52
Reported as:
Mean · units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 24, and 52
units on a scaleTocilizumab
Baseline (n=215)48.70 ± 45.790
Change at Week 2 (n=203)-26.5 ± 44.04
Change at Week 24 (n=176)-38.9 ± 48.75
Change at Week 52 (n=29)-39.3 ± 26.82
Statistical analysis
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
SecondaryPercentage of Participants With an American College of Rheumatology 20% (ACR20), 50% (ACR50), and 70% (ACR70) Response

The ACR 20, 50, and 70 responses: greater than or equal to (\>/=) 20 percent (%), 50%, and 70% improvement in TJC and SJC (28 assessed joints), and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP or ESR at each visit.

Time frame:
Weeks 2, 24, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20), 50% (ACR50), and 70% (ACR70) Response
percentage of participantsTocilizumab
Week 2: ACR 20 (n=222)18.5
Week 2: ACR 50 (n=222)6.3
Week 2: ACR 70 (n=222)11.7
Week 24: ACR 20 (n=192)8.3
Week 24: ACR 50 (n=192)4.7
Week 24: ACR 70 (n=192)65.6
Week 52: ACR 20 (n=70)0.0
Week 52: ACR 50 (n=70)0.0
Week 52: ACR 70 (n=70)40.0
SecondaryPercentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28

The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 \</=3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1; non-responders: change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1.

Time frame:
Baseline, Weeks 2, 24, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
percentage of participantsTocilizumab
Week 2: No Response (n=222)32.4
Week 2: Moderate Response (n=222)50.5
Week 2: Good Response (n=222)17.1
Week 24: No Response (n=192)13.5
Week 24: Moderate Response (n=192)25.0
Week 24: Good Response (n=192)61.5
Week 52: No Response (n=70)55.7
Week 52: Moderate Response (n=70)8.6
Week 52: Good Response (n=70)35.7
SecondaryChange From Baseline in Total TJC at Weeks 2, 24, and 52

TJC was defined as the total number of painful joints based on 68-joint assessment (TJC-68) and 28-joint assessment (TJC-28).

Time frame:
Baseline, Weeks 2, 24, and 52
Reported as:
Mean · tender joints
Change From Baseline in Total TJC at Weeks 2, 24, and 52
tender jointsTocilizumab
TJC-68, Baseline (n=223)16.91 ± 10.860
TJC-68, Change at Week 2 (n=218)-5.4 ± 8.38
TJC-68, Change at Week 24 (n=188)-12.9 ± 11.18
TJC-68, Change at Week 52 (n=69)-16.5 ± 10.35
TJC-28, Baseline (n=224)11.32 ± 6.241
TJC-28, Change at Week 2 (n=219)-3.7 ± 5.40
TJC-28, Change at Week 24 (n=189)-8.6 ± 6.62
TJC-28, Change at Week 52 (n=70)-11.0 ± 6.14
Statistical analysis
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
SecondaryChange From Baseline in Total SJC at Weeks 2, 24, and 52

SJC was defined as the total number of swollen joints based on 66-joint assessment (SJC-66) and 28-joint assessment (SJC-28).

Time frame:
Baseline, Weeks 2, 24, and 52
Reported as:
Mean · swollen joints
Change From Baseline in Total SJC at Weeks 2, 24, and 52
swollen jointsTocilizumab
SJC-66, Baseline (n=223)9.53 ± 6.713
SJC-66, Change at Week 2 (n=218)-3.7 ± 4.94
SJC-66, Change at Week 24 (n=188)-8.3 ± 6.73
SJC-66, Change at Week 52 (n=69)-9.1 ± 6.66
SJC-28, Baseline (n=224)7.90 ± 5.203
SJC-28, Change at Week 2 (n=219)-2.9 ± 3.91
SJC-28, Change at Week 24 (n=189)-6.7 ± 5.17
SJC-28, Change at Week 52 (n=70)-7.6 ± 4.63
Statistical analysis
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
SecondaryAssociation Between Disease Activity Parameters: DAS28-ESR and CDAI, Assessed Using Correlation Coefficient

DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. Higher scores indicate greater affectation due to disease activity. The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. Higher scores represent greater affectation due to disease activity. Correlation coefficient for relationship between DAS28-ESR and CDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship.

Time frame:
Weeks 2, 24, 52
Reported as:
Number · correlation coefficient
Association Between Disease Activity Parameters: DAS28-ESR and CDAI, Assessed Using Correlation Coefficient
correlation coefficientTocilizumab
Week 2 (n=213)0.86514
Week 24 (n=182)0.86944
Week 52 (n=32)0.87301
Statistical analysis
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
SecondaryAssociation Between Disease Activity Parameters: DAS28-ESR and SDAI, Assessed Using Correlation Coefficient

DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. Higher scores indicate greater affectation due to disease activity. SDAI is a numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. Higher scores indicate greater affectation due to disease activity. Correlation coefficient for relationship between DAS28-ESR and SDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship.

Time frame:
Weeks 2, 24, 52
Reported as:
Number · correlation coefficient
Association Between Disease Activity Parameters: DAS28-ESR and SDAI, Assessed Using Correlation Coefficient
correlation coefficientTocilizumab
Week 2 (n=213)0.88118
Week 24 (n=182)0.87060
Week 52 (n=31)0.81995
Statistical analysis
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
SecondaryAssociation Between Disease Activity Parameters: CDAI and SDAI, Assessed Using Correlation Coefficient

The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. Higher scores represent greater affectation due to disease activity. SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. Higher scores indicate greater affectation due to disease activity. Correlation coefficient for relationship between CDAI and SDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship.

Time frame:
Weeks 2, 24, 52
Reported as:
Number · correlation coefficient
Association Between Disease Activity Parameters: CDAI and SDAI, Assessed Using Correlation Coefficient
correlation coefficientTocilizumab
Week 2 (n=213)0.98602
Week 24 (n=185)0.97515
Week 52 (n=31)0.97389
Statistical analysis
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
SecondaryAssociation Between Disease Activity Parameter (DAS28-ESR) and Treatment Response Parameters (ACR20, ACR50, and ACR70), Assessed Using Regression Coefficient

DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. The ACR 20, 50, and 70 responses: \>/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between DAS28-ESR and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.

Time frame:
Weeks 2, 24, 52
Reported as:
Number · regression coefficient
Association Between Disease Activity Parameter (DAS28-ESR) and Treatment Response Parameters (ACR20, ACR50, and ACR70), Assessed Using Regression Coefficient
regression coefficientTocilizumab
Week 2: DAS28-ESR and ACR20 (n=213)-1.02676
Week 2: DAS28-ESR and ACR50 (n=213)-1.31737
Week 2: DAS28-ESR and ACR70 (n=213)-1.50400
Week 24: DAS28-ESR and ACR20 (n=182)-1.71191
Week 24: DAS28-ESR and ACR50 (n=182)-1.54281
Week 24: DAS28-ESR and ACR70 (n=182)-1.43977
Week 52: DAS28-ESR and ACR20 (n=32)-2.05036
Week 52: DAS28-ESR and ACR50 (n=32)-2.05036
Week 52: DAS28-ESR and ACR70 (n=32)-2.05036
Statistical analysis
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = 0.0004
  • Tocilizumab · ANOVA · p = 0.0004
  • Tocilizumab · ANOVA · p = 0.0004
SecondaryAssociation Between Disease Activity Parameter (DAS28-ESR) and Treatment Response Parameter (EULAR), Assessed Using Regression Coefficient

DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. EULAR response criteria (based on DAS28 score): Good responders (change from baseline \>1.2 with DAS28 \</=3.2); Moderate responders (change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1); Non-responders (change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1). Regression coefficient for relationship between DAS28-ESR and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.

Time frame:
Weeks 2, 24, 52
Reported as:
Number · regression coefficient
Association Between Disease Activity Parameter (DAS28-ESR) and Treatment Response Parameter (EULAR), Assessed Using Regression Coefficient
regression coefficientTocilizumab
Week 2: DAS28-ESR and EULAR (n=213)-1.62883
Week 24: DAS28-ESR and EULAR (n=182)-1.36226
Week 52: DAS28-ESR and EULAR (n=32)-1.47781
Statistical analysis
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
SecondaryAssociation Between Disease Activity Parameter (CDAI) and Treatment Response Parameters (ACR20, ACR50, and ACR70), Assessed Using Regression Coefficient

The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. The ACR 20, 50, and 70 responses: \>/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between CDAI and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.

Time frame:
Weeks 2, 24, 52
Reported as:
Number · regression coefficient
Association Between Disease Activity Parameter (CDAI) and Treatment Response Parameters (ACR20, ACR50, and ACR70), Assessed Using Regression Coefficient
regression coefficientTocilizumab
Week 2: CDAI and ACR20 (n=220)-9.65473
Week 2: CDAI and ACR50 (n=220)-10.67389
Week 2: CDAI and ACR70 (n=220)-13.38810
Week 24: CDAI and ACR20 (n=186)-13.18433
Week 24: CDAI and ACR50 (n=186)-11.95933
Week 24: CDAI and ACR70 (n=186)-11.18299
Week 52: CDAI and ACR20 (n=32)-18.94643
Week 52: CDAI and ACR50 (n=32)-18.94643
Week 52: CDAI and ACR70 (n=32)-18.94643
Statistical analysis
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
SecondaryAssociation Between Disease Activity Parameter (CDAI) and Treatment Response Parameter (EULAR), Assessed Using Regression Coefficient

The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. EULAR response criteria (based on DAS28 score): Good responders (change from baseline \>1.2 with DAS28 \</=3.2); Moderate responders (change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1); Non-responders (change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1). Regression coefficient for relationship between CDAI and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.

Time frame:
Weeks 2, 24, 52
Reported as:
Number · regression coefficient
Association Between Disease Activity Parameter (CDAI) and Treatment Response Parameter (EULAR), Assessed Using Regression Coefficient
regression coefficientTocilizumab
Week 2: CDAI and EULAR (n=220)-10.97686
Week 24: CDAI and EULAR (n=186)-7.03184
Week 52: CDAI and EULAR (n=32)-9.46563
Statistical analysis
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
SecondaryAssociation Between Disease Activity Parameter (SDAI) and Treatment Response Parameters (ACR20, ACR50, and ACR70), Assessed Using Regression Coefficient

SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. The ACR 20, 50, and 70 responses: \>/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between SDAI and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.

Time frame:
Weeks 2, 24, 52
Reported as:
Number · regression coefficient
Association Between Disease Activity Parameter (SDAI) and Treatment Response Parameters (ACR20, ACR50, and ACR70), Assessed Using Regression Coefficient
regression coefficientTocilizumab
Week 2: SDAI and ACR20 (n=213)-9.44923
Week 2: SDAI and ACR50 (n=213)-10.74230
Week 2: SDAI and ACR70 (n=213)-13.31421
Week 24: SDAI and ACR20 (n=185)-14.19790
Week 24: SDAI and ACR50 (n=185)-12.65454
Week 24: SDAI and ACR70 (n=185)-11.78067
Week 52: SDAI and ACR20 (n=31)-22.83519
Week 52: SDAI and ACR50 (n=31)-22.83519
Week 52: SDAI and ACR70 (n=31)-22.83519
Statistical analysis
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
SecondaryAssociation Between Disease Activity Parameter (SDAI) and Treatment Response Parameter (EULAR), Assessed Using Regression Coefficient

The SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. EULAR response criteria (based on DAS28 score): Good responders (change from baseline \>1.2 with DAS28 \</=3.2); Moderate responders (change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1); Non-responders (change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1). Regression coefficient for relationship between SDAI and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.

Time frame:
Weeks 2, 24, 52
Reported as:
Number · regression coefficient
Association Between Disease Activity Parameter (SDAI) and Treatment Response Parameter (EULAR), Assessed Using Regression Coefficient
regression coefficientTocilizumab
Week 2: SDAI and EULAR (n=213)-11.73463
Week 24: SDAI and EULAR (n=185)-7.32435
Week 52: SDAI and EULAR (n=31)-9.64146
Statistical analysis
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = <0.0001
  • Tocilizumab · ANOVA · p = 0.0016
SecondaryPercentage of DMARDs Dose Reductions and/or Discontinuation Events by Reasons

Percentage of DMARDs dose reduction and/or discontinuation (Red/Dis) events is reported by different reasons.

Time frame:
Baseline up to Week 52
Reported as:
Number · percentage of events
Percentage of DMARDs Dose Reductions and/or Discontinuation Events by Reasons
percentage of eventsTocilizumab
Safety27.7
Discomfort9.5
Lack of Efficacy29.7
Other Than Above31.1
Unknown2.0
SecondaryPercentage of Non-DMARDs Dose Reductions and/or Discontinuation Events by Reasons

Percentage of Non-DMARDs dose reduction and/or discontinuation (Red/Dis) events is reported by different reasons.

Time frame:
Baseline up to Week 52
Reported as:
Number · percentage of events
Percentage of Non-DMARDs Dose Reductions and/or Discontinuation Events by Reasons
percentage of eventsTocilizumab
Safety9.5
Discomfort1.3
Lack of Efficacy8.8
Other Than Above73.7
Unknown6.8
SecondaryChange From Baseline in PtGDA VAS Score at Weeks 2, 24, and 52

Participants answered the following question: "Considering all the ways your arthritis affects you, how are you feeling today." Participants responded by using a 0 - 100 millimeter (mm) VAS, where 0 mm = very well and 100 mm = very poorly.

Time frame:
Baseline, Weeks 2, 24, and 52
Reported as:
Mean · mm
Change From Baseline in PtGDA VAS Score at Weeks 2, 24, and 52
mmTocilizumab
Baseline (n=226)61.31 ± 23.526
Change at Week 2 (n=220)-10.6 ± 20.99
Change at Week 24 (n=186)-28.4 ± 27.40
Change at Week 52 (n=32)-38.4 ± 27.65
Statistical analysis
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
SecondaryChange From Baseline in PGDA VAS Score at Weeks 2, 24, and 52

The physician assessed participant's current disease activity on a 0-100 mm VAS, where 0 mm = no disease activity and 100 mm = maximum disease activity.

Time frame:
Baseline, Weeks 2, 24, and 52
Reported as:
Mean · mm
Change From Baseline in PGDA VAS Score at Weeks 2, 24, and 52
mmTocilizumab
Baseline (n=226)57.36 ± 19.228
Change at Week 2 (n=220)-15.3 ± 17.49
Change at Week 24 (n=186)-38.0 ± 25.13
Change at Week 52 (n=32)-43.9 ± 17.13
Statistical analysis
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
SecondaryParticipant Pain VAS Score at Weeks 2, 24, and 52

Participants assessed their pain using a 0-100 mm VAS. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain.

Time frame:
Weeks 2, 24, and 52
Reported as:
Mean · mm
Participant Pain VAS Score at Weeks 2, 24, and 52
mmTocilizumab
Baseline (n=226)58.21 ± 23.622
Change at Week 2 (n=220)-11.4 ± 22.38
Change at Week 24 (n=186)-26.5 ± 27.31
Change at Week 52 (n=32)-36.0 ± 26.82
Statistical analysis
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Weeks 2, 24, and 52

HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Baseline, Weeks 2, 24, and 52
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Weeks 2, 24, and 52
units on a scaleTocilizumab
Baseline (n=223)1.04 ± 0.687
Change at Week 2 (n=215)-0.2 ± 0.44
Change at Week 24 (n=183)-0.4 ± 0.63
Change at Week 52 (n=31)-0.5 ± 0.69
Statistical analysis
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
SecondaryMissed Working Days Assessed Using Short Form-Health and Labor Questionnaire (SF-HLQ) Score at Weeks 24 and 52

The SF-HLQ assessed productivity losses related to health problems in individuals with paid or unpaid work and consisted of three modules (absenteeism from paid work, production losses without absenteeism from paid work and hindrance in the performance of paid and unpaid work). Any missed working days or number of worked days with reduced efficiency during the last month were reported.

Time frame:
Weeks 24 and 52
Reported as:
Mean · days
Missed Working Days Assessed Using Short Form-Health and Labor Questionnaire (SF-HLQ) Score at Weeks 24 and 52
daysTocilizumab
Week 24 (n=69)6.4 ± 45.09
Week 52 (n=7)0.3 ± 0.76
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Total Score at Weeks 2, 24, and 52

FACIT total score is sum of Functional Assessment of Cancer Therapy-General (FACT-G) score and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F; additional concerns) score. FACT-G is a core questionnaire that evaluates quality of life (QoL) in cancer population. FACT-G consists of 27 questions grouped in 4 domains of general health-related QoL: physical well-being, social/family well-being, emotional well-being, and functional well-being; each item ranges from 0 (not at all) to 4 (very much). FACT-G score ranges between 0-108. FACIT-F is a 13-item questionnaire that evaluates self-reported fatigue and its impact upon daily activities. Each item ranges from 0 (Not at all) to 4 (Very much). The sum of all responses result in the FACIT total score with a total possible range of 0 (better score) to 160 (worse score). Negative change from baseline represents a better QoL.

Time frame:
Baseline, Weeks 2, 24, and 52
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Total Score at Weeks 2, 24, and 52
units on a scaleTocilizumab
Baseline (n=207)72.41 ± 16.806
Change at Week 2 (n=196)-5.8 ± 14.10
Change at Week 24 (n=165)-11.1 ± 18.60
Change at Week 52 (n=60)-43.8 ± 34.87
Statistical analysis
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = <0.0001
SecondaryChange From Baseline in Pittsburgh Sleep Quality Index (PSQI) at Weeks 24 and 52

PSQI is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction). A participant indicates how frequently each item was experienced on a scale from 0 to 3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality. A score of \>/=5 indicates poor sleepers.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) at Weeks 24 and 52
units on a scaleTocilizumab
Baseline (n=103)11.00 ± 2.719
Change at Week 24 (n=73)-0.7 ± 2.39
Change at Week 52 (n=16)-0.9 ± 2.42
Statistical analysis
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = 0.0045
  • Tocilizumab · Wilcoxon Rank Sum and Signed Rank Tests · p = 0.1992
SecondaryTreatment Compliance, as Assessed Using Participant Diary Cards and Return Records

Treatment Compliance was calculated as (total actual doses taken for the period) / (total planned or prescribed dose for the period) x 100.

Time frame:
Weeks 24 and 52
Reported as:
Mean · percentage of planned dose
Treatment Compliance, as Assessed Using Participant Diary Cards and Return Records
percentage of planned doseTocilizumab
Week 24 (n=221)94.9 ± 10.20
Week 52 (n=222)94.7 ± 10.12
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs) of Special Interest

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs are AEs occurring between the first dose of study drug and up to 28 days after the last dose that were absent before treatment or that worsened relative to pre-treatment state. Following AEs were considered as AEs of special interest: anaphylactic reaction, hypersensitivity, stress cardiomyopathy, Gilbert's syndrome, gastrointestinal perforation, injection site erythema, injection site hypersensitivity, injection site irritation, injection site pruritus, arthritis bacterial, cellulitis, klebsiella infection, oral candidiasis, pneumonia, skin infection, vulvovaginal candidiasis, alanine aminotransferase increased, hepatic enzyme increased, brain neoplasm malignant, and urticaria.

Time frame:
Baseline up to 95 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) of Special Interest
percentage of participantsTocilizumab
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) of Special Interest7.5
SecondaryPercentage of Participants With Anti-Therapeutic Antibodies (ATA) to Tocilizumab

Percentage of participants with positive results for ATA against tocilizumab at different time points is reported.

Time frame:
Baseline, Weeks 12, 24, 38, 52, at 8 weeks after last dose (up to Week 60), at early withdrawal (up to Week 52), at Follow-up Visits 1 (Week 64), 2 (Week 76), and 3 (Week 88)
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to Tocilizumab
percentage of participantsTocilizumab
Baseline (n=227)2.6
Week 12 (n=6)100.0
Week 24 (n=179)1.7
Week 38 (n=6)33.3
Week 52 (n=161)1.2
8 Weeks After Last Dose (up to Week 60) (n=41)2.4
Early Withdrawal (up to Week 52) (n=31)6.5
Follow-up Visit 1 (Week 64) (n=16)100.0
Follow-up Visit 2 (Week 76) (n=11)100.0
Follow-up Visit 3 (Week 88) (n=3)100.0
SecondaryMean Tocilizumab Concentration
Time frame:
Baseline, Weeks 12, 24, 38, 52, at early withdrawal (up to Week 52), at Follow-up Visit 2 (Week 76)
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Mean Tocilizumab Concentration
micrograms per milliliter (mcg/mL)Tocilizumab
Baseline (n=2)35.6 ± 48.89
Week 12 (n=186)46.4 ± 23.01
Week 24 (n=177)52.6 ± 28.21
Week 38 (n=169)55.2 ± 30.55
Week 52 (n=165)54.0 ± 29.00
Early Withdrawal (up to Week 52) (n=19)24.8 ± 22.90
Follow-up Visit 2 (Week 76) (n=17)49.2 ± 34.05
SecondaryMean Soluble Interleukin-6 Receptor (sIL-6R) Concentration
Time frame:
Baseline, Weeks 12, 24, 38, 52, at early withdrawal (up to Week 52), at Follow-up Visit 2 (Week 76)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Mean Soluble Interleukin-6 Receptor (sIL-6R) Concentration
nanograms per milliliter (ng/mL)Tocilizumab
Baseline (n=213)43.6 ± 49.30
Week 12 (n=189)543.9 ± 144.34
Week 24 (n=181)536.3 ± 144.32
Week 38 (n=171)557.8 ± 144.23
Week 52 (n=168)539.4 ± 147.04
Early Withdrawal (up to Week 52) (n=32)329.1 ± 257.30
Follow-up Visit 2 (Week 76) (n=18)523.4 ± 161.14

Adverse events

Collected over Day 1 up to approximately 95 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab—17/227 (7.5%)36/227 (15.9%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventTocilizumab
Stress cardiomyopathyCardiac disorders1/227
PneumoniaInfections and infestations1/227
Skin infectionInfections and infestations1/227
Humerus fractureInjury, poisoning and procedural complications1/227
Wrist fractureInjury, poisoning and procedural complications1/227
Carcinoembryonic antigen increasedInvestigations1/227
Hepatic enzyme increasedInvestigations1/227
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/227
Ovarian cystReproductive system and breast disorders1/227
PleurisyRespiratory, thoracic and mediastinal disorders1/227
Most frequent other events
Most frequent other events
EventTocilizumab
InfluenzaInfections and infestations23/227
CoughRespiratory, thoracic and mediastinal disorders16/227
Transaminases increasedInvestigations15/227
BronchitisInfections and infestations15/227
Urinary tract infectionInfections and infestations12/227

Baseline characteristics

Full Analysis Set (FAS) included all recruited participants who received at least one dose of SC tocilizumab.

Age, Continuous
Age, Continuous(years)Tocilizumab
Mean54.7 ± 12.12
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab
Female197
Male30
08

Study locations

49 sites
  • Uni Degli Studi Di L Aquila; Cattedra Di Reumatologia - Dept. Di Medicina Interna E San
    Coppito, Abruzzo 67100, Italy
  • P. O. Spirito Santo - Asl Pescara; U.O. Complessa Di Reumatologia
    Pescara, Abruzzo 65100, Italy
  • Azienda Ospedaliera Bianchi Melacrino Morelli; Unità Operativa di Reumatologia
    Reggio Calabria, Calabria 89133, Italy
  • Az. Ospedaliera S. Giuseppe Moscati; Dip. Med. Gen. Struttura Semplice Reumatologia
    Avellino, Campania 83100, Italy
  • Azienda Ospedaliera Rummo; Divisione Di Reumatologia
    Benevento, Campania 82100, Italy
  • Azienda Ospedaliera A. Cardarelli; Medicina III - Divisione di Reumatologia
    Napoli, Campania 80131, Italy
  • Policlinico Universitario-II Università di Napoli; Reumatologia
    Napoli, Campania 80131, Italy
  • Osp Riuniti S.Giovanni di Dio e Ruggi d'Aragona; Rep. Medicina Interna
    Salerno, Campania 84131, Italy
  • Irccs Fondazione Salvatore Maugeri-Istituto Scientifico Di Telese;U.O. Riabilitazione Reumatologica
    Telese Terme, Campania 82037, Italy
  • A.O.U Policlinico S. Orsola Malpighi di Bologna U.O di Medicina Interna Borghi - Pad.2
    Bologna, Emilia-Romagna 40138, Italy
  • A.O. Universitaria Policlinico Di Modena; Reumatologia
    Modena, Emilia-Romagna 41100, Italy
  • Arcispedale Santa Maria Nuova; Reumatologia
    Reggio Emilia, Emilia-Romagna 42100, Italy
  • Policlinico Univ. Uni Degli Sudi Di Udine; Clinica Di Reumatologia
    Udine, Friuli-Venezia Giulia 33100, Italy
  • Policlinico Campus Bio-Medico Di Trigoria; Medicina Clinica E Reumatologia
    Roma, Lazio 00128, Italy
  • Policlinico Tor Vergata; Divisione Di Reumatologia
    Roma, Lazio 00133, Italy
  • Ospedale S.Pietro Fatebenefratelli; Divisione di Reumatologia
    Roma, Lazio 00189, Italy
  • Ospedale La Colletta; Reparto Di Reumatologia
    Arenzano, Liguria 16011, Italy
  • Università Degli Studi Di Genova - Dimi; Reumatologia
    Genova, Liguria 16132, Italy
  • Ospedale San Paolo; Divisione di Reumatologia
    Savona, Liguria 17100, Italy
  • Asst Papa Giovanni XXIII; Dh Reumatologia
    Bergamo, Lombardia 24127, Italy
  • Ospedale Civile "La Memoria" Di Gavardo;Immunoematologia Trasfusionale-Allergologia E Reumatologia
    Gavardo, Lombardia 25085, Italy
  • Ospedale Di Magenta Fornaroli; U.O. Di Reumatologia
    Magenta, Lombardia 20013, Italy
  • Asst Centro Specialistico Ortopedico Traumato-Logico Gaetano Pini/Cto; Divisione Di Reumatologia
    Milano, Lombardia 20122, Italy
  • Ospedale Maggiore Policlinico; Unità Operativa Complessa di Allergologia e Immunologia Clinica
    Milano, Lombardia 20122, Italy
  • ASST FATEBENEFRATELLI SACCO; Reumatologia (Sacco)
    Milano, Lombardia 20157, Italy
  • Asst Grande Ospedale Metropolitano Niguarda; Reumatologia
    Milano, Lombardia 20162, Italy
  • ASST DI MONZA; Reumatologia (Medicina I)
    Monza, Lombardia 20052, Italy
  • Irccs Policlinico San Matteo; Reumatologia Adulti
    Pavia, Lombardia 27100, Italy
  • ASST DI VIMERCATE; Medicina Generale
    Vimercate, Lombardia 20059, Italy
  • Ospedale Regionale Torrette; SOD Clinica Medica del Dipartimento di Medicina Interna e Specialisti
    Ancona, Marche 60020, Italy
  • Ospedale Murri - Universita Politecnica Delle Marche; Clinica Reumatologica Ii
    Jesi, Marche 60035, Italy
  • Azienda Ospedaliera Maggiore Della Carita; Day Hospital Immunologia
    Novara, Piemonte 28100, Italy
  • Azienda Ospedaliera San Giovanni Battista; Reparto Reumatologia
    Torino, Piemonte 10126, Italy
  • Ordine Mauriziano Ospedale Umberto I; Centro Di Reumatologia
    Torino, Piemonte 10128, Italy
  • Azienda Ospedaliera Policlinico; Servizio Reumatologia
    Bari, Puglia 70124, Italy
  • ASL Lecce- Presidio Ospedaliero di Casarano-Servizio di Reumatologia ed Osteoporosi
    Casarano (LE), Puglia 73042, Italy
  • Ospedali Riuniti di Foggia; Dipartimento Medicina Interna Reumatologia
    Foggia, Puglia 71100, Italy
  • Ospedali Riuniti Di Foggia; Struttura Di Reumatologia
    Foggia, Puglia 71100, Italy
  • A.O. Universitaria Policlinico Monserrato Di Cagliari; Reumatologia I
    Cagliari, Sardegna 09042, Italy
  • Azienda Ospedaliero Universitaria di Sassari; UOC Reumatologia
    Sassari, Sardegna 07100, Italy
  • Ospedale Vittorio Emanuele Ii; U.O. Reumatologia Clinica Medica Condorelli
    Catania, Sicilia 95124, Italy
  • Azienda Osped. Univ. Policlinico G. Martino; Centro Prevenzione E Cura Osteoporosi
    Messina, Sicilia 98100, Italy
  • Arnas Ospedale Civico; Medicina Interna II
    Palermo, Sicilia 90127, Italy
  • Ospedale Careggi Villa Monnatessa ; Sezione Di Reumatologia
    Firenze, Toscana 50139, Italy
  • Az. Osp. Pisana Ospedale S. Chiara; U.O. Di Reumatologia
    Pisa, Toscana 56100, Italy
  • Osp S. Maria Misericordia Dip. Medicina Clinica Sperimentale Cattedra Reumatologia
    Perugia, Umbria 06122, Italy
  • Ospedale Regionale Umberto Parini; Reparto Endocrinologia e Diabetologia - Amb. Reumatologia
    Aosta, Valle D'Aosta 11100, Italy
  • Azienda Ospedaliera Universitaria Borgo Trento; Dipartimento di Medicina Sezione di Reumatologia
    Verona, Veneto 37126, Italy
  • Policlinico G.B. Rossi; Divisione Immunologia Clinica Sperimentale Medicina B
    Verona, Veneto 37134, Italy
09

References and documents

Publications

  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Petho-Schramm A. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393. PubMed 30649524 ↗
  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Petho-Schramm A. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Erratum In: Rheumatology (Oxford). 2018 Jun 1;57(6):1129. doi: 10.1093/rheumatology/key116. PubMed 29244149 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Sep 2015, 24 months.

Results were first posted in Dec 2016, 1 year 3 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 24 months is close to that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2013
First posted
Sep 13, 2013
StartActual
Sep 5, 2013
Primary completionActual
Sep 9, 2015
CompletionActual
Jul 5, 2016
Results first posted
Dec 15, 2016
Last update
Jul 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01941940
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 13, 2013
Start date
Sep 5, 2013
Primary completion
Sep 9, 2015
Completion
Jul 5, 2016
Results posted
Dec 15, 2016
Last update
Jul 11, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion